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SUMMARY
Background: This study was aimed at estimating the 
human papillomavirus (HPV) prevalence and its de-
terminants among a sample of Ghanaian women. 
Design: Cross-sectional observational study.
Setting: Gynaecology outpatient clinic of the Korle-Bu 
Teaching Hospital, Accra, Ghana; the largest tertiary 
care gynaecology outpatient clinic in Ghana.
Participants: Convenient sample of 75 consenting 
women visiting the clinic.
Methods: Information was obtained through personal 
interviews using structured questionnaire, Pap smears 
obtained, and laboratory testing of cervical exfoliated 
cells was performed. HPV DNA was detected using a 
GP5+/6+ polymerase chain reaction assay. These data 
were analyzed using both univariate and bivariate tech-
niques. 
Results: The mean age of participants was 33.3 years 
(standard deviation, 9.2) and the percentage of lifetime 
monogamy was 21.3%. The crude HPV DNA preva-
lence was 10.7%. Unlike most populations studied so 
far, HPV prevalence was high not only among young 
women, but also in middle and old age. Independent 
HPV determinants were being illiterate (prevalence 
odds ratio [POR], 13.9; 95% confidence interval 
[95%CI], 1.9-100) and reporting more than three life-
time sexual partners (POR, 4.6; 95% CI, 1.0-22.2). 
Conclusions: The study indicates a high crude preva-
lence of HPV in a largely polygamous Ghanaian popu-
lation with a high crude prevalence in older age groups, 
which may be a distinctive feature of polygamous 
populations where HPV transmission continues into 
middle age and cervical cancer incidence is very high.   
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INTRODUCTION
Human papillomaviruses (HPVs) are aetiological 
agents of cervical intraepithelial neoplasia and cervical 
cancer. Cervical cancer claims the lives of an estimated 
231,000 women annually, with over 80% of these 
deaths occurring in developing countries. Cervical can-
cer is the most common female malignancy in sub-
Saharan Africa.1 The incidence of cervical cancer in 
sub-Saharan Africa is among the highest worldwide, 
with the available age-standardised rates ranging from 
19.9 per 100,000 in Ibadan, Nigeria,1 through 35.7 per 
100,000 in Bamako, Mali, to 41.7 per 100,000 in 
Kyadondo, Ugandan.2 The prevalence of cervical HPV 
infection varies greatly worldwide. Population-based 
HPV prevalence surveys have shown a 13-fold varia-
tion in sexually-active women aged 15-65 years, rang-
ing from 2.0% in Hanoi, North Vietnam,3 3.0% in Bar-
celona, Spain,4 14.8% in Bogota, Columbia,5 through 
17.7% in Concordia, Argentina,6 to the highest of 
26.3% in Ibadan, Nigeria,7  a West African neighbour 
of Ghana.
Genital HPVs are common sexually transmitted viruses 
and the high-risk types (HR-HPV) have been shown to 
be the cause of invasive cervical cancer and its cyto-
logical precursors, squamous intraepithelial lesions.8-10
Additionally, the prevalence of HR-HPV types in mid-
dle-aged women and the incidence of cervical cancer in 
the same age group are strongly positively correlated.11  
The prevalence of genital HPV is also directly related 
to the number of lifetime sexual partners, recent change 
in sexual partners, marital status, illiteracy, oral contra-
ceptive use, alcoholism, smoking, hormonal and die-
tary factors, and immunosuppression.7,12-14  HPV 16 is 
the most common HPV type found in the cervix and in 
cervical cancers, where it is detected in over 50% of 
cases.  The other types detected commonly in cervical 
cancers include types 18, 45 and 31.15
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Recently available information on the prevalence of 
cervical HPV infection in subsets of the sexually-active 
female population in sub-Saharan Africa16-26  show 
comparably high prevalence rates to that found in the 
population-based survey in Nigeria,7  with some varia-
tions based on the sample selection and the type of 
HPV testing employed. Organized cytology screening 
programs have reduced the incidence of and mortality 
from cervical carcinoma in many developed countries, 
but the Papanicoloau (Pap) screening test is not avail-
able routinely in sub-Saharan Africa. Because cyto-
logical or HPV screening programs based on frequently 
repeated screening rounds would be expensive, logisti-
cally difficult and not feasible in many developing 
countries, immunization against HR-HPV offers the 
greatest hope for a long-term solution to cervical can-
cer. In the short-term, though, early detection of cervi-
cal neoplasia with visual inspection with acetic acid 
(VIA), now considered as a low-technology alternative 
to cervical cytology, is currently being evaluated in 
Ghana and other developing countries.27
The understanding of the behavioural characteristics 
that relate to the acquisition of HPV infections is im-
portant to identify subgroups within a population that 
are at higher risk for invasive cervical cancer. Using 
dot blot to detect the presence of HPV DNA, the evi-
dence of cervical HPV infection was reported in 33% 
and 48% of rural and urban women in Ghana, respec-
tively.28 Here, we report the first PCR-based molecular 
study of cervical HPV infection in Ghana, and its cor-
relates to the socio-demographic and reproductive 
characteristics of Ghanaian women.
SUBJECTS AND METHODS
Study area and subjects
This study was conducted at the Gynecology Outpa-
tient Clinic of the Korle-Bu Teaching Hospital 
(KBTH), Accra, Ghana, between January and April 
2002.  KBTH, situated in the nation’s capital, Accra, is 
the leading tertiary hospital and the major referral cen-
ter in the country.  Hence, most of the patients seen at 
KBTH are referral cases from various parts of Southern 
Ghana. It also serves as the teaching hospital of the 
University of Ghana Medical School.  Thus the demo-
graphics of the patients that were tested in this study 
were not limited to a specific social group, such as 
commercial sex workers, who are expected to attend 
Gynaecological clinics more frequently.  The patients 
in this study originated from various social and ethnic 
groups as well as geographically distinct areas from the 
vast territory of the Greater Accra region and the 
Southern part of Ghana.  There was no selection of 
patients from a larger cohort of HPV-tested cases; the 
cases presented here were the first 75 consecutive pa-
tients to enter the Gynaecology Clinic who consented 
to participate in the study and a request for HPV test-
ing.  The inclusion criteria required a patient’s consent 
to take part in the study and the consented patient 
should not have any form of vaginal bleeding or dis-
charge at the time of the study.  Eighteen patients ful-
filling the above inclusion criteria declined participa-
tion before we accrued our desired sample size of 75, 
and the major reason offered was their lack of familiar-
ity with the Papanicoloau test procedure on account of 
no previous history of Pap testing.  The protocol for the 
study was approved by the Ethical and Protocol Re-
view Committee of the University of Ghana Medical 
School.
Questionnaire
After an explanation of the study to each patient at 
their appropriate level of literacy, and following writ-
ten informed consent, information was obtained from 
each consenting participant through personal inter-
views using structured questionnaire (including when 
necessary translation of the purpose, written informed 
consent form and the questionnaire of the study into 
local Ghanaian languages) assessing sociodemographic 
characteristics, sexual history, knowledge about cervi-
cal cancer, gynecological history as it relates to the risk 
factors associated with HPV infections. 
Sample collection and DNA Extraction
Following completion of the questionnaire by personal 
interview, a consultant gynaecologist performed a gy-
naecological examination.  After the examination, ec-
tocervical and endocervical samples were obtained 
(from each patient) for the extraction of DNA for the 
detection of HPV.  Briefly, a sterile vaginal speculum 
was inserted into the vagina of the patient, and using a 
sterile Ayre’s spatula, exfoliated cells were obtained 
from the transformation zone of the cervix.  The spat-
ula was then rinsed in sterile phosphate buffer (PBS, 
pH 7.4), centrifuged (2,000g, 5 min), and the super-
natant discarded.  The pellets were placed in a micro-
centrifuge tube with 50 µl of lysing buffer solution 
containing 2.5 mM MgCl2, 50 mM KCl, 10 mM Tris 
HCl, pH 8.3, and 0.5% Tween 20.  Two microliters of 
proteinase K (QIAGEN, GmbH, Germany) was also 
added and the mixture incubated at 56oC for 2 hours.  
The samples were spun (2,000g, 2 min) briefly, and 
then incubated (95oC for 10 minutes) to denature the 
residual protease.  The digested samples were centri-
fuged at 2,000g, for 2 minutes and 5µl of the super-
natant of each sample was used directly, without puri-
fication, as DNA template for PCR amplification.
PCR Primers and Amplification
To analyze the quality of target DNA for PCR testing, 
5µl of the supernatant of each of the 75 samples were 
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screened with β-globin gene-specific control primers 
(M24191),29 and all 75 samples produced a positive β-
globin result. General consensus primers GP5+ 
(5’TTTGTTGTGGTAGATACTC 3’) and 
GP6+ (5’GAAAAATAAACTGTAAATCATATTC 3’) 
were used (Invitrogen Life Technologies, Frederick, 
MD, U.S.A).  Amplification reactions were done using 
5 µl of DNA (0.5% to 2% of the total extractable 
DNA) as DNA template, in a 50 µl reaction mixture 
containing 50 mM KCl, 10 mM Tris HCl (pH 8.8), 3.6 
mM, 0.1 mg BSA/ml, 2.5 µl deoxynucleoside triphos-
phate, and IU of Taq polymerase (QIAGEN).  Fifty 
picomoles of each primer were used for the ultrasensi-
tive amplification as previously described.30,31 HPV 
negative control samples (K562 human DNA cell line 
DNA) were interspersed between clinical specimens to 
evaluate potential inter-specimen contamination. Posi-
tive control samples (HPV positive cell line CaSki 
cells, 600 viral copies of HPV DNA/cell) were inter-
spersed between clinical specimens to monitor the 
overall amplification and hybridization process. The 
negative and positive control specimens were proc-
essed with all clinical specimens and each individual 
hybridization reaction tray contained at least 1 positive 
and 1 negative control.
PCR Product Visualization
Amplified DNA fragments were separated in 2% aga-
rose gel by electrophoresis and stained with ethidium 
bromide (0.5 mg/ml). The UV-illuminated gels were 
photographed with Kodak (type DC265, Epson, Suwa, 
Japan) digital camera. Electrophoresis was read by 
comparison with the DNA molecular weight lad-
der/markers, and a positive result was identified by 
corresponding to the 140 bp fragment of the amplified 
HPV positive control sample (HPV positive cell line 
CaSki cells).
Data Analysis
The Statistical Analysis System (SAS Institute, Cary, 
NC) version 9.1 was used to complete all data analyses. 
The categories of some of the characteristics were 
combined into only two groups to avoid large confi-
dence intervals, on account of our small study popula-
tion size. The women were divided into 2 categories of 
age; less than or equal to 30 years and greater than 30 
years. Educational levels were classified as illiterate or 
better; contraceptive use as barrier or non barrier; age 
at first sexual intercourse was divided into less than or 
equal to 18 years and greater than 18 years; number of 
life time partners as less than or equal to 3 and more 
than 3.In the univariate analysis, the frequencies for 
each of the variables above were calculated. The 
means, median, maximum and minimum values for 
age, age at first sexual intercourse and number of life-
time sexual partners were determined. The univariate 
analysis of age was repeated after having stratified by 
serum analysis results and compared the mean ages for 
statistically significant difference using the Student’s T 
Test. In the bivariate analysis, odds ratios for HPV 
positivity and corresponding 95% confidence intervals 
were calculated by means of unconditional, multiple 
logistic regression equations adjusted for age (continu-
ous variable). 
RESULTS
The 75 study participants had a mean age of 33.3 years 
(standard deviation, 9.2 years; range, 19 to 57 years). 
The vast majority (90.7%) had at least primary level of 
education and 9.3% were illiterates. The majority 
(85.3%) were married (with 16.4% in a polygamous 
marriage) and 14.7% were single, divorced or wid-
owed.  Fifty (66.7%) had their first sexual intercourse 
by age 18, with the earliest age being 14 years. The 
percentage of lifetime monogamy was 21.3%, with
78.7% of the study participants having had 2 or more 
lifetime sexual partners. Their mean number of lifetime 
sexual partners was 2.5, with the maximum number 
being 6. Sixty-seven (89.3%) had never used a female 
condom, whereas only 8 (10.7%) had ever used a con-
dom. Fifty-six percent (42 out of 75) had heard of cer-
vical cancer, but only one study participant knew it is 
caused by HPV infection. Of the 42 study participants 
who had heard of cervical cancer, 20 (47.6%) knew 
that it could be prevented but only one study partici-
pant knew that it could be prevented specifically by 
performing the Pap smear test. Thirty-four (45.3%), 24 
(32.0%), and 4 (5.3%) respectively, had histories of 
pelvic pain, offensive vaginal discharge and genital 
warts.
Figure 1 Gel photograph of simple Human Papillomavirus 
PCR products. The 140 bp fragment corresponds to the am-
plified HPV DNA. Lane M: 100bp DNA molecular weight 
marker; NC: negative control (no DNA); PC: positive control 
June 2008 A.B. Domfeh et al. HPV Prevalence in Ghanaian Women
74
(HPV positive cell line CaSki cells); S1 and S2: HPV DNA 
positive samples 1 and 2, respectively.
Figure 1 shows the 2% agarose gel electrophoresis 
photograph of the products of the simple PCR amplifi-
cation of the HPV DNA in the cervical scrapes. Gen-
eral consensus primers GP5+ and GP6+ were used to 
amplify the HPV L1 gene region of the HPV DNA. 
This synthesizes a 140 bp fragment. Of the 75 cervical 
scrapes, positive HPV DNA PCR amplification was 
achieved in 8, giving a crude HPV DNA prevalence of 
10.7%. DNA from these 8 specimens gave bands in the 
region of 140 bp, suggesting that the correct regions of 
the HPV DNA has been amplified and confirming the 
presence of HPV infection in these patients. The preva-
lence of HPV was highest (18.2%) among women 41-
50 years of age, followed by 10.7% in 21-30 year 
group, then 10% in 31-40 year group, and 0% in 11-
21 and 51-60 year groups. The mean age of the 8 HPV 
DNA positive women was 30.5 years (standard devia-
tion, 9.1 years; range, 22 to 46 years), whilst the mean 
age of the 67 HPV DNA negative women was 33.6 
years (standard deviation, 9.2 years; range, 19 to 57 
years). There was no statistically significant difference 
(T test, t = 0.91, p = 0.4 > 0.05) between the mean 
ages of the HPD DNA positive and negative women.
Table 1 shows the odds ratios (ORs) for HPV DNA 
positive detection and corresponding 95% confidence 
intervals (95%CIs) according to the sociodemographic 
and reproductive behavioural characteristics among 75 
women in Accra, Ghana. Illiteracy, which was re-
ported by 9.3% of women, was associated with a OR 
for HPV DNA detection of 13.9 (95%CI, 1.9 – 100). 
Women reporting more than 3 lifetime sexual part-
ners, who accounted for 20% of our study partici-
pants, had 4.6-fold (95%CI, 1.0 – 22.2) higher HPV 
DNA prevalence as compared with women reporting 3 
or less lifetime sexual partners. Women older than 30 
years, who accounted for 57.3% of our study partici-
pants, were at an increased risk (OR, 2.1; 95%CI, 0.5 
– 9.3) of HPV DNA detection as compared with 
women younger than 30 years, though the differences 
in prevalence estimates did not reach statistical sig-
nificance. Sexual intercourse at 18 years of age or 
younger, reported by 66.7% of women, was associated 
with a OR for HPV DNA detection of 2.1 (95%CI, 0.4 
– 10.4), but differences did not reach the level of statis-
tical significance. Condom use was not associated with 
HPV DNA detection (OR, 0.9; 95%CI, 0.1 – 9.4). 
DISCUSSION
The study group included women that were largely 
polygamous with multiple lifetime sexual partners, 
relatively early age at first sexual intercourse and very
low lifetime use of condoms. This profile is consistent 
with the reported high incidence of cervical cancer in 
Ghana and other sub-Saharan African countries,1,2  and 
previous reports of high prevalence of cervical HPV 
infection in Ghana28 and other sub-Saharan African 
countries.7,16-24 The prevalence of HPV DNA detection 
of 10.7% found in women in Accra, Ghana is in the 
upper end of the world spectrum,3-7 and consistent with 
previous reports in women in sub-Saharan African.7,16-
24
Table 1: Odds Ratios (ORs) for Positive HPV DNA 
Detection and corresponding 95% Confidence Intervals 
(95% CIs) according to the sociodemographic and re-
productive behavioural characteristics among 75 
women in Accra, Ghana
a Combined into only two categories to minimize the width of 
confidence intervals.
b Adjusted for age.
Previous cervical HPV prevalence studies in sub-
Saharan Africa have generally shown relatively high 
prevalence with some variations, based on the sample 
selection and the type of HPV testing employed. Poly-
merase chain reaction (PCR)-based assays, similar to 
a Characteristic Number 
of 
Women







< 30 34 3 (8.8) 1
> 30 41 5 (12.2) 2.1 
(0.5 – 9.3)
Age at first sexual intercourse (years)
< 18 50 6 (12.0) 2.1 
(0.4 – 10.4)
> 18 25 2 (8.0) 1
Formal educational level achieved
Primary or 
Better
68 5 (7.4) 1
Illiterate or 
None
7 4 (57.1) 13.9 
(1.9 - 100)
Condom (male & female types) use
Never 67 7 (10.4) 0.9 
(0.1 – 9.4)
Ever 8 1 (12.5) 1
Number of lifetime sexual partners
< 3 60 4 (6.7) 1
> 3 15 4 (26.7) 4.6 
(1.0 – 22.2)
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that employed in this study, showed HPV prevalence of 
44% in Nairobi, Kenya,24 40% in rural Mozambique,18
34% in Northwestern Tanzania,19,23 31% in Harare, 
Zimbabwe,20 26.3% in Ibadan, Nigeria,7 18% in Dakar 
and Pikene, Senegal,22  and 15.4% in South Africa.21
The hybrid capture assay II showed HPV prevalence of 
25% in Harare, Zimbabwe,17  and 17% in rural 
Uganda.16  Using dot blot to detect the presence of 
HPV DNA, the evidence of cervical HPV infection was 
previously reported in 33% and 48% of rural and urban 
women in Ghana, respectively,28  compared to the 
10.7% herein reported using the more specific PCR-
based assay. 
The reported age pattern of HPV prevalence differs 
from one country to another, but the predominant re-
ported pattern shows an early peak in the young age 
groups, soon after the start of sexual intercourse,32 
followed by a steady decline in middle age, after clear-
ance of a large proportion of newly acquired infections, 
and a steady state in the age group 40 and above.3-6,32,33 
In some populations, U-shaped curves, with a second 
peak in postmenopausal women, were found, and this 
observation has generally been detected in countries 
with high incidence rates of cervical cancer.32-35 In 
three previous studies from sub-Saharan Africa,16,18,24  
the prevalence of HPV declined significantly with age. 
In two other sub-Saharan African studies,7,22 HPV 
prevalence showed no significant decline with age, and 
indeed, in one of these two studies22 high-risk, and not 
low-risk HPV types, were more frequently detected in 
older than younger women. The age-specific point 
prevalence of cervical HPV infection of the study 
group was notable, with a peak among women 41-50 
years of age, followed by women in 21-30 year group, 
then women in 31-40 year group, and finally women in 
11-21 and 51-60 year groups. The age pattern of HPV 
prevalence of the study group was U-shaped, with a 
higher second peak, and consistent with the general 
observation in countries with high cervical cancer inci-
dence rates like Ghana.36  In Ghana, cervical cancer is 
the third most common cause of cancer mortality in 
women, accounting for 8.47% of cancer deaths in Gha-
naian women.36  Additionally, the age pattern of HPV 
prevalence of the study group showed a general in-
crease, there was no statistically significant differences 
in the age-specific rates of HPV DNA detection in the 
study women aged 30 and older compared to the study 
women younger than 30 years of age (Table 1).  The 
explanations for the persistent high prevalence of HPV 
in middle and older aged women, and the peak HPV 
prevalence in the 41-50 year group (peri- and post-
menopausal women) in Accra, Ghana are not obvious 
from this study. HPV prevalence age pattern similar to 
that of the study group in Accra, Ghana has previously 
been reported in two populations as very high-risk for 
cervical cancer, namely Chennai, Southern India18 and 
Ibadan, Nigeria.7 Hormonal changes as well as changes 
in sexual behaviour among peri- and post-menopausal 
women and their partners might both contribute to this 
observation. Specifically, in the Ghanaian and Nigerian 
societies where polygamy is generally accepted, a frac-
tion of men and women (mainly men) may continue to 
have multiple sexual partners throughout their life and 
therefore reinfect themselves and their spouses. Addi-
tionally, as previously suggested,7  women in develop-
ing countries, like Ghana, Nigeria and India, may have 
decreased ability to clear HPV infections, possibly due 
to concomitant genital infections or nutritional defi-
ciencies, since the development of an efficient immune 
response against HPV acquired over age is the gener-
ally accepted reason for the decline in HPV prevalence 
observed in other populations.3-6,32 The group of 
women who remain persistent carriers of HPV by mid-
dle age are now considered the high-risk group for cer-
vical cancer.3-7,32-35   
Being illiterate and reporting more than 3 lifetime sex-
ual partners were the main correlates of HPV DNA 
detection among the study women. This confirms the 
findings of previous studies that demonstrated that the 
number of lifetime sexual partners4,14 and illiteracy7
are significantly associated with HPV infection. The 
previously identified barriers to the early detection of 
cervical cancer in Ghana were the low level of knowl-
edge about cervical cancer etiology, pap smear test and 
cervical cancer screening.37 These barriers were con-
firmed in this study group, with the knowledge about 
cervical cancer, its’ causes and prevention being very 
poor. This poses a tremendous health education chal-
lenge, since majority of the women studied are not 
even aware of the disease and the steps to prevent it 
from occurring. Therefore, increasing the proportion of 
population with formal education as well as intensify-
ing health education would be necessary to reduce the 
prevalence of HPV infection and the incidence of cer-
vical cancer in Ghana. Adolescents who have not yet 
had sexual intercourse should be educated, counseled 
and encouraged to postpone sexual initiation as long as 
possible. The general public should be educated on 
cervical cancer aetiology, the pap smear test and cervi-
cal cancer screening, and the importance of limiting the 
number of sexual partners and choosing sexual partners 
who have not themselves had multiple sexual partners. 
Female condom use and delayed onset of sexual inter-
course by the study group were not protective against 
HPV infection, and therefore the previously reported 
protective effect of condom use3, 4, 12, 14 and delayed 
onset of sexual intercourse14 against HPV infection 
could not be confirmed. This may be due to the small 
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sample size of the study group.  Despite combining 
some of the characteristics of our study participants 
into only two categories for the univariate and bivariate 
analysis, the relatively wide confidence intervals above 
is due to our small sample size.  Additionally, our sam-
ple of 75 women may not be representative of the gen-
eral Ghanaian population on account of the small sam-
ple size and the convenient sampling method em-
ployed.
CONCLUSION
In conclusion, this study suggests a high prevalence of 
HPV infection in some age groups of the largely po-
lygamous Ghanaian female population as in other sub-
Saharan African countries, and that the initiation of 
sexual intercourse before age 18 and illiteracy are as-
sociated with HPV infection. This has implications for 
extending the reach of formal education and for the 
design of adolescent-specific cervical cancer health 
educational programs in Ghana. However, the findings 
and conclusions of this study are limited by the small 
sample size of participants, and a much larger popula-
tion-based study would be required to validate our 
findings.
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